肺癌患者血清中巨噬细胞抑制因子-1水平初探

Value of serum MIC-1 level in lung cancer patients

目的初步研究肺癌患者血清中巨噬细胞抑制因子-1(MIC-1)的浓度在肺癌临床中的应用价值。方法采用双抗体夹心ELISA法检测79例肺癌患者、8例肺良性疾病患者及200例正常对照人群血清MIC-1浓度,采用电化学发光免疫分析仪检测上述肺癌患者血清标本CEA、CA125、NSE、SCC、Cyfer21浓度。结果肺癌组患者血清中MIC-1浓度显著高于正常对照组(P<0.001)和良性疾病组(P=0.005);根据ROC曲线和正常人群的MIC-1血清水平,设定1000 pg/ml作为诊断肺癌的临界值时,特异性和敏感性分别为97%和66.6%;MIC-1诊断肺癌的敏感性优于已有标志物CEA、CA125、NSE、SCC、Cyfer21;尤其在Ⅰ期患者中,其敏感性甚至优于上述五种标志物联合诊断(70.8%vs50.0%)。结论本研究首次报道MIC-1成为肺癌新的血清标志物的可能性,在肺癌诊断,特别是在肺癌的早期诊断方面MIC-1显示出良好的应用前景。

Objective To study the clinical value of serum macrophages inhibitory cytokine-1 （ MIC-1 ） level in patients with lung cancers. Methods The double antibody sandwich ELISA was used to detect serum MIC-1 level in 79 lung cancer patients （ lung cancer group） , 8 benign pulmonary disease patients （ benign disease group） and 200 bealthy persons （normal control group）. ELC were used to detect the serum CA125, CEA, NSE, SCC and Cyfer21 level. Results MIC-1 concentration in lung cancer group was significantly higher than that in normal control group （P 〈0. 001 ） and benign disease group （ P = 0. 005 ）. According to ROC curve and MIC-1 level of normal control group, when 1000pg/ml of MIC-1 as the eut-off value, the specificity and sensitivity were 97% and 64.6% , respectively. MIC-1 for lung cancer was much than CEA, CA125, NSE, SCC and Cyfer21. Moreover in the I stage patients, sensitive than the combination of the above five markers （70.8% vs 50.0% ）. Conclusion MIC61 may be a new serum marker for lung cancer. It shows a good application prospect in lung cancer, especially in t^e early stage of lung cancer.